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Letters to the EditorInsulin resistance and HCV virologic response to
peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV
co-infected patientsTo the Editor:
In the recently published article by Merchante et al. [1] insulin
resistance, analyzed as HOMA value [(fasting insulin mU/
ml  fasting glucose mmol/l)/22.5)], was not associated with sus-
tained virologic response (SVR) to anti-HCV combination therapy
in HIV/HCV co-infected patients. In that retrospective cohort
study, 36% of 155 patients achieved SVR. At multivariate analysis,
HCV genotype 3, lower baseline HCV-RNA and higher baseline
LDL-cholesterol were independently correlated to SVR. On the
contrary, the HOMA index, considering a cut-off of 4, did not
show any correlation with SVR, even after excluding cirrhotic
patients from the analysis.
In our clinic, we retrospectively analyzed 86 HIV/HCV co-
infected patients treated with Peg-IFN with RBV. At HCV treat-
ment initiation their median age was 42 years, 67% were males,
77% injecting drug users, 88% on combination anti-retroviral
treatment (cART), their median CD4 was 478 cells/mm3; 85%
had HCV-RNA >400,000 IU/ml, 33% with HCV genotype 3, 64%
HCV genotype 1 or 4; 30% showed a Metavir ﬁbrosis score of
F3–F4. Patients were treated with Peg-IFN + RBV (80% Peg-IFN
a2a) for a median of 43.1 weeks (41% of patients reaching
48 weeks of treatment). Fasting IR was determined at baseline,
12 and 48 weeks of HCV therapy. IR was calculated using the
HOMA index (IRP 2.6), Quicki index (IR 60.33) and McAuley
index (IR 65.8) and the different values were correlated with
early virologic response (12 weeks, EVR), end of treatment
response (ETR) and sustained virological response (SVR) by logis-
tic regression analysis. EVR was achieved in 67.4%, ETR in 66.2%,
SVR in 37.2%. IR at baseline 12 and 48 weeks was 2.0 (Q1–Q3 1.4–
3.3), 2.1 (1.4–3.3) and 2.1 (1.3–4.1), according to HOMA index;
0.34 (0.32–0.36), 0.34 (0.32–0.36) and 0.34 (0.31–0.37) according
to Quicki index and 6.4 (5.3–7.3), 5.9 (4.6–7.1) and 6.0 (4.7–7.5),
according to McAuley index, respectively. No signiﬁcant longitu-. Crude associations of different insulin resistance indexes with virological ou
pes (univariate logistic regression).
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represent odds ratios (95% conﬁdence intervals). EVR, early virological response
Journal of Hepatology 20dinal changes of the IR indexes were observed. HCV genotype 3
was weakly associated with a lower baseline McAuley index
(mean difference 0.77 p = 0.06). Genotype 3 was the only vari-
able signiﬁcantly associated with any type of response: EVR
(OR vs genotype 1 or 4: 6.6, 95%CI 2.1–21), ETR (8.38;2.66–
26.41) and SVR (6.96;2.81–17.23). Moreover, baseline HCV-
RNA <400,000 IU/ml also signiﬁcantly predicted SVR (OR 0.22;
0.07–0.70). Concerning IR measures, only baseline or week 12
Quicki index 60.33 showed a slight correlation with reduced
probability of ETR (p = 0.048), while no other IR index showed
an association with any other end-point, even in the analysis
stratiﬁed by viral genotype (see Table 1).
Our data showed similar results compared with those of
Merchante et al. The two case series are quite similar for baseline
characteristics, as well as for outcomes of anti-HCV treatment
(36% vs 37.2% of SVR), suggesting the absence of relevant biases.
In both studies IR was not correlated with anti-HCV treatment
response, considering not only SVR, as Merchante et al. did, but
also EVR and ETR as we did. Moreover, we tried to explore IR
indexes other than HOMA (Quicki and McAuley) failing to ﬁnd
any relevant correlation with treatment outcome except for a
slight association between Quicki index and ETR. In agreement
with the study of Merchante et al. our study conﬁrms the lack
of a relevant role of IR in predicting SVR in HIV/HCV co-infected
patients. Moreover, our data indicate that IR does not predict
virological response to anti-HCV treatment in any HCV genotype
group.
In contrast to these studies, Nasta and coworkers [2] identi-
ﬁed a signiﬁcant association between IR and rapid virological
response (RVR, achievement of undetectable HCV-RNA at week
4: 27% of probability in patients with IR vs 54% in those without).
They did not evaluate either ETR or SVR, so that we cannot spec-
ulate about the consistency of the results with a more stringenttcomes of HCV therapy in all HCV/HIV co-infected patients and divided by HCV
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end-point of anti-HCV therapy such as SVR. Moreover, they
showed a negative correlation between protease inhibitor-based
cART and RVR, indirectly conﬁrmed by the ﬁnding of a detrimen-
tal effect of insulin resistance on HCV treatment in HIV/HCV co-
infected patients [3,4]. Since in our case series as well as that of
Merchante et al. – both consisting mostly of patients on PI-based
cART – no correlation between insulin resistance and ETR/SVR
response to HCV treatment was found, even when limiting the
analysis to patients assuming PI (data not shown), we therefore
conclude that PI-based regimens are not responsible for the
impaired response to treatment when considering more stringent
end-points.
In conclusion, differently from what was observed in HCV
mono-infected population, the exact correlation between IR and
response to HCV treatment in HIV/HCV co-infected patients is
still not clariﬁed. Although patients with IR have been demon-
strated to achieve a poorer initial virologic response in another
study, this ﬁnding was not conﬁrmed by two studies, including
the present one, with more prolonged and stringent evaluations
of treatment efﬁcacy. Larger analyses are warranted in order to
deﬁnitely assess the role of IR in anti-HCV treatment response
in this population.Journal of Hepatology 20References
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